Infliximab as first-line therapy for Crohn's disease

被引：0
|
作者：
Bernstein, CN
机构：
来源：
INFLAMMATORY BOWEL DISEASES | 2002年 / 8卷 / 01期
关键词：
D O I：
10.1097/00054725-200201000-00012
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：63 / 65
页数：3
相关论文
共 50 条
  • [21] Perianal Crohn's disease and infliximab therapy
    McNamara, DA
    Brophy, S
    Hyland, JMP
    SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND, 2004, 2 (05): : 258 - 263
  • [22] Treatment of Crohn's disease with infliximab: first choice?
    Rocha Malheiros, Anna Paula
    Teixeira, Magaly Gemio
    Neto, Arceu Scanavini
    Silva Filho, Edesio Vieira
    de Oliveira Rodrigues, Leonardo Correa
    Thierry, Roberta
    Nahas, Sergio
    Cecconello, Ivan
    ABCD-ARQUIVOS BRASILEIROS DE CIRURGIA DIGESTIVA-BRAZILIAN ARCHIVES OF DIGESTIVE SURGERY, 2009, 22 (02): : 101 - 104
  • [23] The Effectiveness and Safety of Methotrexate as the First-Line Immunomodulator of Maintenance Therapy in Pediatric Crohn Disease
    Choi, Young Min
    Kim, Jeong Min
    Moon, Jin Soo
    Ko, Jae Sung
    Yang, Hye Ran
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2023, 76 (05): : 596 - 602
  • [24] First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?
    Peyrin-Biroulet, Laurent
    Fiorino, Gionata
    Buisson, Anthony
    Danese, Silvio
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2013, 10 (06) : 345 - 351
  • [25] Outcome of infliximab therapy in pediatric Crohn's disease: The first three years experience
    Sant'Anna, AMGA
    Gervais, F
    Deslandres, C
    Seidman, EG
    GASTROENTEROLOGY, 2004, 126 (04) : A458 - A459
  • [26] First-line infliximab is cost-effective compared to conventional treatment in paediatric Crohn's Disease - Results from the TISKids study
    Vuijk, S.
    Jongsma, M.
    Hoeven, B.
    Cozijnsen, M.
    van Pieterson, M.
    de Meij, T.
    Norbruis, O.
    Groeneweg, M.
    Wolters, V.
    van Wering, H.
    Hummel, T.
    Stapelbroek, J.
    van der Feen, C.
    van Rheenen, P.
    van Wijk, M.
    Teklenburg, S.
    Poleij, M.
    Escher, J.
    de Ridder, L.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I111 - I112
  • [27] Randomised clinical trial: First-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn's disease
    Vuijk, Stephanie A.
    Jongsma, Maria M. E.
    Hoeven, Britt M.
    Cozijnsen, Maarten A.
    van Pieterson, Merel
    de Meij, Tim G. J.
    Norbruis, Obbe F.
    Groeneweg, Michael
    Wolters, Victorien M.
    van Wering, Herbert
    Hummel, Thalia
    Stapelbroek, Janneke
    van Der Feen, Cathelijne
    van Rheenen, Patrick F.
    van Wijk, Michiel P.
    Teklenburg, Sarah
    Rizopoulos, Dimitris
    Poley, Marten J.
    Escher, Johanna C.
    de Ridder, Lissy
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 (12) : 1510 - 1520
  • [28] First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?
    Laurent Peyrin-Biroulet
    Gionata Fiorino
    Anthony Buisson
    Silvio Danese
    Nature Reviews Gastroenterology & Hepatology, 2013, 10 : 345 - 351
  • [29] Adherence rates with infliximab therapy in Crohn's disease
    Kane, S.
    Dixon, L.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 24 (07) : 1099 - 1103
  • [30] Infliximab maintenance therapy for fistulizing Crohn's disease
    Brechmann, T
    MEDIZINISCHE KLINIK, 2006, 101 (05) : 423 - 424
12345